Kidney Effects in the MOXIe Trial: Presentation at ERA-EDTA 2020

Friedreich’s Ataxia (FA) is a rare, progressive, and debilitating genetic disorder with no approved treatments. Kidney function was assessed in patients with Friedreich’s ataxia in Part 2 of MOXIe, a Phase 2 international, multicenter, double-blind, randomized, placebo-controlled study of omaveloxolone in FA.

Keap1/Nrf2 Pathway Regulates GFR by Increasing the Glomerular Effective Filtration Area Without Affecting the Afferent/Efferent Arteriole Ratio: Presentation at ERA-EDTA 2020

Pharmacologic and genetic investigation of the mechanisms of GFR regulation by Nrf2 using in vivo multiphoton microscope (MPM) imaging techniques.